Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial

6/10/24 7:09:17 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $RPTX alert in real time by email

Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company's camonsertib monotherapy non-small cell lung cancer (NSCLC) expansion of the TRESR clinical trial.

Get the next $RPTX alert in real time by email

Date	Price Target	Rating	Analyst
6/9/2023	$11.00 → $16.00	Hold → Buy	Stifel
2/3/2023	$28.00 → $15.00	Overweight → Equal-Weight	Morgan Stanley
1/6/2023	$28.00	Overweight	CapitalOne
4/12/2022	$11.00	Buy → Hold	Stifel
3/17/2022	$43.00	Buy	Goldman
9/23/2021	$48.00	Buy	Stifel
9/13/2021	$54.00	Buy	HC Wainwright & Co.
8/16/2021	$45.00 → $47.00	Overweight	Morgan Stanley

Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial

Chat with this insight

Recent Analyst Ratings for
$RPTX

Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial

Chat with this insight

Recent Analyst Ratings for $RPTX

Recent Analyst Ratings for
$RPTX